Physician

Venkatasiva Reddy Peram, M.D.

According to 2025 Medicare claims, Venkatasiva Peram, M.D. (NPI: 1881617702) practices hematology/oncology in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is VENKATASIVA PERAM MD, PC (NPI: 1588783963; TIN: 161727756) and primary practice location at 48507-3966.

Peram's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 366 traditional Medicare patients, billed 166,293 HCPCS/CPT codes, and received $1,741,257 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,573 prescription claims across 270 beneficiaries totaling $2,731,989 in drug costs, led by Erleada (Apalutamide). DME data shows 25 claims. Open Payments data shows 52 records totaling $1,094. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	648	274,558	$1,747,627
2016	615	244,639	$1,803,181
2017	534	299,145	$2,212,834
2018	445	189,515	$1,453,157
2019	461	211,203	$1,684,155
2020	384	213,409	$1,852,394
2021	383	189,227	$1,619,388
2022	376	179,262	$1,764,541
2023	398	163,526	$1,589,678
2024	366	166,293	$1,741,257

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	261	1,552	$2,472,681
2016	262	1,481	$2,950,371
2017	261	1,388	$2,128,433
2018	279	1,457	$2,660,297
2019	271	1,445	$2,853,038
2020	218	1,278	$3,229,260
2021	213	1,176	$3,526,800
2022	217	1,180	$2,935,148
2023	245	1,446	$2,887,357
2024	270	1,573	$2,731,989

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	144	$56,621
2016	N/R	73	$27,313
2017	N/R	40	$14,381
2018	N/R	60	$9,566
2019	N/R	67	$8,132
2020	N/R	30	$3,485
2021	N/R	34	$2,620
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	25	$676

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	137	168	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	205	460	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	117	485	$60
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	63	198	$43
36415	Insertion of needle into vein for collection of blood sample	135	361	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	25	750	$364,032
Revlimid	Lenalidomide	19	532	$362,232
Cabometyx	Cabozantinib S-Malate	12	360	$289,598
Venclexta	Venetoclax	24	700	$287,501
Promacta	Eltrombopag Olamine	22	660	$286,233

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$538
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	52	$1,094	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Venkatasiva Reddy Peram, M.D.?

Tedicare shows public-source Medicare data for Venkatasiva Reddy Peram, M.D. (NPI 1881617702), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Venkatasiva Reddy Peram, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Venkatasiva Reddy Peram, M.D.?

Venkatasiva Reddy Peram, M.D. is linked to VENKATASIVA PERAM MD, PC (billing NPI 1588783963) in the available physician profile data.

Does Venkatasiva Reddy Peram, M.D. have Open Payments data?

Venkatasiva Reddy Peram, M.D. has 52 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.